Advertisement

Reactions Weekly

, Volume 1765, Issue 1, pp 173–173 | Cite as

Fluorouracil/folinic acid/oxaliplatin

Development of resistance in metastatic colorectal cancer: 4 case reports
Case report
  • 18 Downloads

In a comparative study, 2 men and 2 women in their 60s [exact ages at the time of reactions onsets not stated] were described, who developed resistance during adjuvant chemotherapy with mFOLFOX6 regimen consisting of fluorouracil, folinic-acid and oxaliplatin for metastatic colorectal cancer (CRC) [routes, times to reaction onsets and outcomes not stated; not all dosages stated].

Case 1: A man in his late 60s had undergone colectomy and hepatic resection of the primary sigmoid colon cancer and colorectal metastases. He received 3 cycles of mFOLFOX6 regimen consisting of oxaliplatin [L-OHP] 85 mg/m2every 14 days along with fluorouracil [5-fluorouracil] and folinic-acid [leucovorin]. Following 3 cycles of mFOLFOX6 chemotherapy, recurrence was noted in the remnant liver. Later he received one more cycle of the chemotherapy. Cytogenetic analysis revealed mutations clusters related to GO:0006816~calcium ion transport and GO:0005509~calcium ion binding, which conferred chemo-resistance,...

Reference

  1. Harada K, et al. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. BMC Cancer 19: 1-11, Part 255, 12 Mar 2019. Available from: URL: http://doi.org/10.1186/s12885-019-5479-6 - Japan

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations